Go Pro
→ Your withdrawal order could cost you in taxes (From SmartAsset) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$4.96
-4.2%		$5.79
$4.83
▼
$8.74
$71.97M0.412,074 shs8,154 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-4.25%-2.17%-19.09%-17.47%-33.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$4.96
-4.2%		$5.79
$4.83
▼
$8.74
$71.97M0.412,074 shs8,154 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-4.25%-2.17%-19.09%-17.47%-33.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CSBR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2026
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/15/2026
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/22/2026
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$59.42M1.16$0.01 per share356.11$0.29 per share17.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$1.17M-$0.08N/AN/AN/A-1.87%-27.48%-3.84%9/14/2026 (Estimated)

Latest CSBR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/14/2026Q1 2027
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$0.01N/AN/AN/A$15.05 millionN/A
7/27/2026Q4 2026
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$0.05$0.01+$0.06-$0.05$12.89 million$13.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
0.96
0.96

Institutional Ownership

CompanyInstitutional Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%

Insider Ownership

CompanyInsider Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
46.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
14313.89 million7.37 millionOptionable

Recent News About These Companies

Reviewing Champions Oncology (NASDAQ:CSBR) & Rapid Micro Biosystems (NASDAQ:RPID)
August 22 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975568
Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving Average - Here's Why
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/champions-oncology-nasdaqcsbr-stock-price-crosses-below-200-day-moving-average-heres-why-2026-08-04/
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
July 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2964901/csbr-stock-dips-post-q4-earnings-despite-record-revenue-growth-ai-push?cid=cs-stocknewsapi-ft-microcap_article|earnings-2964901
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
July 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4926002-champions-oncology-inc-csbr-q4-2026-earnings-call-transcript
Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $59 Million
July 27, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69136039-champions-oncology-inc-champions-oncology-reports-record-annual-revenue-of-dollar-59-million-200.htm
Champions Oncology Q4 Earnings Call Highlights
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/champions-oncology-q4-earnings-call-highlights-2026-07-27/
Champions Oncology (NASDAQ:CSBR) Releases Earnings Results, Hits Estimates
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/champions-oncology-nasdaqcsbr-releases-earnings-results-hits-estimates-2026-07-27/
Champions Oncology Reports Record Annual Revenue of $59 Million
July 27, 2026  |  accessnewswire.comA
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
July 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2959626/csbr-vs-ctkb-which-life-sciences-stock-has-better-long-term-upside?cid=cs-stocknewsapi-ft-microcap_article|investment_ideas-2959626
2 Microcaps With Gross Margin Catalysts
July 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2958775/2-microcaps-with-gross-margin-catalysts?cid=cs-stocknewsapi-ft-microcap_article-2958775
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
July 22, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2958305/zacks-initiates-coverage-of-champions-oncology-with-neutral-recommendation?cid=cs-stocknewsapi-ft-microcap_article-2958305
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
July 20, 2026  |  accessnewswire.comA
Champions Oncology, Inc.: Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
April 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68161816-champions-oncology-inc-champions-oncology-to-present-new-data-on-predicting-response-and-resistance-at-aacr-2026-200.htm
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
April 9, 2026  |  accessnewswire.comA
Champions Oncology, Inc.: Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
March 31, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68078020-champions-oncology-inc-champions-oncology-names-brian-alexander-to-board-as-company-advances-data-driven-oncology-strategy-200.htm
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
March 30, 2026  |  accessnewswire.comA
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2026 Earnings Call Transcript
March 14, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/champions-oncology-inc-nasdaqcsbr-q3-2026-earnings-call-transcript-1716205/
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
March 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4881889-champions-oncology-inc-csbr-q3-2026-earnings-call-transcript
Champions Oncology Reports Revenue of $16.6 Million
March 12, 2026  |  accessnewswire.comA
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
March 5, 2026  |  accessnewswire.comA
Is Champions Oncology, Inc.'s (NASDAQ:CSBR) Latest Stock Performance A Reflection Of Its Financial Health?
January 17, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/champions-oncology-inc-nasdaq-csbr-121726160.html

Media Sentiment Over Time

Champions Oncology stock logo

Champions Oncology NASDAQ:CSBR

$4.96 -0.22 (-4.25%)
As of 08/21/2026 03:49 PM Eastern

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas